Online inquiry

IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7580MR)

This product GTTS-WQ7580MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CSF3R gene. The antibody can be applied in Neutropenia research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
RefSeq NM_000760.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1441
UniProt ID Q99062
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ7580MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11522MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ10586MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY-3127804
GTTS-WQ540MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 4D5-8
GTTS-WQ5830MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ11907MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ1116MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-927
GTTS-WQ5019MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA c4G7-N
GTTS-WQ13935MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-2810
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW